Tazuma S, Sasaki H, Mizuno S, Sagawa H, Hashiba S, Horiuchi I, Kajiyama G
First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Gastroenterology. 1989 Jul;97(1):173-8. doi: 10.1016/0016-5085(89)91432-7.
The object of this study was to determine the effects of ursodeoxycholic acid administration on metastability in human gallbladder bile, as reflected by nucleation time. Bile samples from 10 patients with cholesterol gallstones who underwent preoperative ursodeoxycholic acid treatment exhibited a significantly longer median nucleation time (16 days) than those from 11 patients with cholesterol gallstones who received no preoperative treatment (4 days) (p less than 0.01). On the other hand, the median nucleation times of bile samples from 15 patients with noncholesterol gallstones and 24 patients without gallstones were 15 and 14 days, respectively. In addition, 3 mo of treatment with ursodeoxycholic acid significantly elevated the serum concentration of the antinucleating factor apolipoprotein A-I, from 133.3 +/- 12.3 to 148.6 +/- 13.2 mg/dl (p less than 0.05). These findings suggest that ursodeoxycholic acid retards cholesterol crystal nucleation, thereby inhibiting cholesterol gallstone formation. It is also possible that serum apolipoprotein A-I plays a role in this process.
本研究的目的是确定服用熊去氧胆酸对人胆囊胆汁亚稳定性的影响,以成核时间作为反映指标。10例接受术前熊去氧胆酸治疗的胆固醇结石患者的胆汁样本,其成核时间中位数(16天)显著长于11例未接受术前治疗的胆固醇结石患者(4天)(p<0.01)。另一方面,15例非胆固醇结石患者和24例无结石患者的胆汁样本成核时间中位数分别为15天和14天。此外,熊去氧胆酸治疗3个月显著提高了抗成核因子载脂蛋白A-I的血清浓度,从133.3±12.3mg/dl升至148.6±13.2mg/dl(p<0.05)。这些发现表明,熊去氧胆酸可延缓胆固醇晶体成核,从而抑制胆固醇结石形成。血清载脂蛋白A-I也可能在此过程中发挥作用。